Yatin Suneja Analyst Performance

Biotechnology Research Analyst - Specializes in I&I, CNS at Guggenheim

Yatin Suneja is a stock analyst at Guggenheim in the medical sector, covering 41 publicly traded companies. Over the past year, Yatin Suneja has issued 75 stock ratings, including buy and hold recommendations. While full access to Yatin Suneja's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yatin Suneja's coverage history, rating activity, and performance tendencies â€” helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 136 Last 10 Years
Buy Recommendations: 86.03% 117 Buy Ratings
Companies Covered: 41 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	86.0%	117 ratings
Hold	14.0%	19 ratings
Sell	0.0%	0 ratings

Out of 136 total stock ratings issued by Yatin Suneja at Guggenheim, the majority (86.0%) have been Buy recommendations, followed by 14.0% Hold.

Best & Worst Calls

Best Call
0000.0%
PHAT
May 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
AXSM
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	97.6% of companies on NASDAQ	40 companies
NYSE	2.4% of companies on NYSE	1 company

Yatin Suneja, an analyst at Guggenheim, currently covers 41 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 41 companies	100.0%

Yatin Suneja of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 33 companies	80.5%
MED - DRUGS 5 companies	12.2%
PHARMACEUTICAL PREPARATIONS 2 companies	4.9%
BIOTECHNOLOGY 1 company	2.4%

About Yatin Suneja

Mr. Suneja is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector, with over 16 years of experience in equity research. Since joining Guggenheim in 2018, he has provided in-depth analysis and investment insights on biotechnology companies, with a particular focus on those in the immunology, neurology, and inflammatory (INI) space. Previously, he was a Managing Director at SunTrust Robinson Humphrey and a Vice President at Cowen & Company, both specializing in biotechnology equity research. He began his career in Corporate Banking at Bank of America. Mr. Suneja holds an M.B.A. from Syracuse University and a B.Com from PGDAV College, University of Delhi.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ALMS Alumis	5/15/2026	Boost Price Target	$24.63	$34.00	Buy
ARGX argenex	5/8/2026	Boost Price Target	$787.31	$1,135.00	Buy
NBIX Neurocrine Biosciences	5/6/2026	Reiterated Rating	$144.75	$175.00	Buy
AXSM Axsome Therapeutics	5/4/2026	Boost Price Target	$227.50	$260.00	Buy
DBVT DBV Technologies	5/4/2026	Reiterated Rating	$19.10	$51.00	Buy
REGN Regeneron Pharmaceuticals	5/1/2026	Boost Price Target	$704.44	$995.00	Buy
BIIB Biogen	4/30/2026	Boost Price Target	$194.38	$260.00	Buy
ORKA Oruka Therapeutics	4/27/2026	Set Price Target	$80.91	$200.00	Buy
IFRX InflaRx	4/21/2026	Reiterated Rating	$1.63	$14.00	Buy
ORKA Oruka Therapeutics	4/13/2026	Reiterated Rating	$61.89	$125.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
NMRA Neumora Therapeutics	3/31/2026	Reiterated Rating	$1.93	$14.00	Buy
DBVT DBV Technologies	3/27/2026	Reiterated Rating	$20.21	$51.00	Buy
AXSM Axsome Therapeutics	3/25/2026	Boost Price Target	$158.75	$245.00	Buy
IMUX Immunic	3/24/2026	Initiated Coverage	$11.70	$70.00	Buy
CABA Cabaletta Bio	3/24/2026	Boost Price Target	$2.70	$16.00	Buy
IFRX InflaRx	3/20/2026	Lower Price Target	$0.91	$14.00	Buy
ZBIO Zenas BioPharma	3/16/2026	Boost Price Target	$23.23	$55.00	Buy
ORKA Oruka Therapeutics	3/13/2026	Reiterated Rating	$31.99	$60.00	Buy
ACET Adicet Bio	3/13/2026	Lower Price Target	$7.04	$100.00	Buy
XENE Xenon Pharmaceuticals	3/9/2026	Reiterated Rating	$62.63	$90.00	Buy
SION Sionna Therapeutics	3/2/2026	Boost Price Target	$33.68	$50.00	Buy
ARGX argenex	2/27/2026	Lower Price Target	$771.53	$1,120.00	Buy
PHAT Phathom Pharmaceuticals	2/27/2026	Boost Price Target	$12.94	$25.00	Buy
AXSM Axsome Therapeutics	2/24/2026	Boost Price Target	$174.76	$220.00	Buy
PRAX Praxis Precision Medicines	2/10/2026	Reiterated Rating	$319.54	$800.00	Buy
BIIB Biogen	2/9/2026	Boost Price Target	$201.18	$246.00	Buy
IMVT Immunovant	2/9/2026	Boost Price Target	$27.05	$44.00	Buy
REGN Regeneron Pharmaceuticals	2/9/2026	Boost Price Target	$784.43	$975.00	Buy
STOK Stoke Therapeutics	2/5/2026	Initiated Coverage	$32.00	$60.00	Buy
STOK Stoke Therapeutics	2/5/2026	Initiated Coverage	$32.40	$60.00	Buy
AVTX Avalo Therapeutics	2/2/2026	Initiated Coverage	$15.11	$50.00	Buy
RAPT Rapt Therapeutics	1/20/2026	Downgrade	$57.52		Neutral
ALMS Alumis	1/7/2026	Boost Price Target	$16.23	$32.00	Buy
AXSM Axsome Therapeutics	1/2/2026	Reiterated Rating	$177.09	$205.00	Buy
PRAX Praxis Precision Medicines	12/29/2025	Reiterated Rating	$301.40		Buy
SABS SAB Biotherapeutics	12/19/2025	Initiated Coverage	$3.95	$15.00	Buy
SABS SAB Biotherapeutics	12/19/2025	Initiated Coverage	$3.84	$15.00	Buy
IMVT Immunovant	12/18/2025	Reiterated Rating	$26.98	$41.00	Buy
ANAB AnaptysBio	12/18/2025	Reiterated Rating	$45.60		Buy
ABVX Abivax	12/18/2025	Reiterated Rating	$110.82	$175.00	Buy
Are we ignoring the same signal Wall Street ignored in 1929? (Ad) In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $500 into a fortune while the average stock lost 90% of its value. His son Martin later digitized those same formulas into Weiss Ratings, a system now tracking 22,000 stocks with 1.2 billion daily calculations. That system called the bank failures of the 1980s, the dot-com bust, 2008, and the 2020 crash. Right now it is flashing Code Red - issuing Must-Sell warnings on 10 widely held US stocks and upgrading 3 under-the-radar names to an urgent Buy. Access the full briefing at 79% off during the Memorial Day Savings Event. Watch the market briefing and claim your 79% Memorial Day discount now
DBVT DBV Technologies	12/17/2025	Reiterated Rating	$17.98	$51.00	Buy
PRAX Praxis Precision Medicines	12/9/2025	Reiterated Rating	$270.98	$760.00	Buy
DBVT DBV Technologies	12/3/2025	Initiated Coverage	$12.90	$35.00	Buy
DBVT DBV Technologies	12/3/2025	Initiated Coverage	$12.99	$35.00	Buy
ROIV Roivant Sciences	11/14/2025	Reiterated Rating	$20.56	$25.00	Buy
IFRX InflaRx	11/10/2025	Boost Price Target	$1.23	$22.00	Buy
PRAX Praxis Precision Medicines	11/6/2025	Reiterated Rating	$172.35	$540.00	Buy
ANAB AnaptysBio	11/5/2025	Boost Price Target	$36.13	$100.00	Buy
AXSM Axsome Therapeutics	11/4/2025	Boost Price Target	$134.39	$205.00	Buy
PHAT Phathom Pharmaceuticals	10/30/2025	Reiterated Rating	$13.31	$20.00	Buy
REGN Regeneron Pharmaceuticals	10/29/2025	Boost Price Target	$654.48	$865.00	Buy
ORKA Oruka Therapeutics	10/27/2025	Initiated Coverage	$27.25	$60.00	Buy
RAPT Rapt Therapeutics	10/27/2025	Initiated Coverage	$29.53	$70.00	Buy
NMRA Neumora Therapeutics	10/27/2025	Upgrade	$2.63	$14.00	Buy
PRAX Praxis Precision Medicines	10/16/2025	Set Price Target	$189.69	$350.00	Buy
ABVX Abivax	10/10/2025	Boost Price Target	$90.61	$150.00	Buy
ACET Adicet Bio	10/8/2025	Boost Price Target	$13.65	$128.00	Buy
MLTX MoonLake Immunotherapeutics	9/30/2025	Lower Price Target	$6.24	$20.00	Buy
ACET Adicet Bio	9/19/2025	Reiterated Rating	$12.97	$112.00	Buy
ARGX argenex	9/18/2025	Reiterated Rating	$734.77	$1,070.00	Buy
ROIV Roivant Sciences	9/18/2025	Boost Price Target	$15.42	$21.00	Buy
TRML Tourmaline Bio	9/10/2025	Reiterated Rating	$47.64	$48.00	Neutral
TRML Tourmaline Bio	9/9/2025	Downgrade	$47.64		Hold
DNTH Dianthus Therapeutics	9/9/2025	Boost Price Target	$31.80	$100.00	Buy
FBRX Forte Biosciences	8/18/2025	Initiated Coverage	$11.57	$75.00	Buy
FBRX Forte Biosciences	8/18/2025	Initiated Coverage	$11.49	$75.00	Buy
TRML Tourmaline Bio	8/14/2025	Reiterated Rating	$21.88	$55.00	Buy
REGN Regeneron Pharmaceuticals	8/1/2025	Boost Price Target	$545.46	$815.00	Buy
NBIX Neurocrine Biosciences	8/1/2025	Boost Price Target	$126.03	$175.00	Buy
ARGX argenex	8/1/2025	Boost Price Target	$667.75	$1,070.00	Buy
ABVX Abivax	7/23/2025	Boost Price Target	$10.00	$101.00	Buy
LRMR Larimar Therapeutics	6/24/2025	Reiterated Rating	$2.42	$26.00	Buy
ALMS Alumis	6/10/2025	Upgrade	$3.43	$18.00	Buy
ANAB AnaptysBio	5/28/2025	Reiterated Rating	$21.95	$90.00	Buy
VIGL Vigil Neuroscience	5/22/2025	Set Price Target	$7.88	$8.00	Neutral
CABA Cabaletta Bio	5/15/2025	Boost Price Target	$1.70	$25.00	Buy
ARGX argenex	5/9/2025	Lower Price Target	$547.89	$1,065.00	Buy
ANAB AnaptysBio	5/6/2025	Boost Price Target	$20.97	$54.00	Buy
NBIX Neurocrine Biosciences	5/6/2025	Boost Price Target	$125.03	$165.00	Buy
PHAT Phathom Pharmaceuticals	5/2/2025	Lower Price Target	$2.76	$12.00	Buy
REGN Regeneron Pharmaceuticals	5/1/2025	Lower Price Target	$589.21	$810.00	Buy
PHAT Phathom Pharmaceuticals	4/2/2025	Reiterated Rating	$5.98		Buy
CABA Cabaletta Bio	4/1/2025	Reiterated Rating	$1.32	$23.00	Buy
ZURA Zura Bio	3/26/2025	Reiterated Rating	$1.37	$15.00	Buy
IFRX InflaRx	3/26/2025	Boost Price Target	$1.33	$10.00	Buy
LRMR Larimar Therapeutics	3/25/2025	Reiterated Rating	$2.29	$26.00	Buy
IMVT Immunovant	3/20/2025	Reiterated Rating	$18.84		Buy
DNTH Dianthus Therapeutics	3/12/2025	Reiterated Rating	$23.06	$84.00	Buy
ARGX argenex	3/10/2025	Boost Price Target	$575.37	$1,100.00	Buy
IMVT Immunovant	3/10/2025	Reiterated Rating	$20.28		Buy
Are we ignoring the same signal Wall Street ignored in 1929? (Ad) In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $500 into a fortune while the average stock lost 90% of its value. His son Martin later digitized those same formulas into Weiss Ratings, a system now tracking 22,000 stocks with 1.2 billion daily calculations. That system called the bank failures of the 1980s, the dot-com bust, 2008, and the 2020 crash. Right now it is flashing Code Red - issuing Must-Sell warnings on 10 widely held US stocks and upgrading 3 under-the-radar names to an urgent Buy. Access the full briefing at 79% off during the Memorial Day Savings Event. Watch the market briefing and claim your 79% Memorial Day discount now
NMRA Neumora Therapeutics	3/7/2025	Downgrade	$1.52		Neutral
NBIX Neurocrine Biosciences	2/10/2025	Lower Price Target	$122.62	$163.00	Buy
IMVT Immunovant	2/10/2025	Lower Price Target	$20.41	$44.00	Buy
VIGL Vigil Neuroscience	1/24/2025	Reiterated Rating	$2.49		Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.